BioSpace News Archive

iCAD, Inc. announced it signed an amendment to its development and commercialization agreement with Google Health, which will enable iCAD to integrate Google’s AI technology with its ProFound Breast Health Suite for 2D Mammography for use worldwide upon regulatory approval as an independent reader for breast cancer screening for 20 years.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2023.

Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended June 30, 2023, and recent business highlights.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2023 and provided a business update.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, announced its second quarter 2023 financial results and provided recent operating highlights for the clinical programs in ALS and MS.

Kelyniam Global, a maker of custom cranial implants, announced results for its half year ended June 30, 2023.

Rockwell Medical, Inc., a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced financial results and business updates for the three and six months ended June 30, 2023.

TherapeuticsMD, Inc., a company that owns rights to pharmaceutical royalties, reported financial results for the second quarter ended June 30, 2023.

LAVATherapeuticsN.V. (Nasdaq:LVTX) today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the H.C. Wainwright Immune Cell Engager Virtual Conference.

PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), today announced the submission to the U.S. Food and Drug Administration (FDA) of an updated Chemistry, Manufacturing and Controls (CMC) package and a Phase 3 multicenter registrational protocol to the company’s Investigational New Drug (IND) submission to evaluate the combination of PDS0101 and KEYTRUDA.